OpenAI is planning to bring over more researchers from Thinking Machines Lab after nabbing two cofounders, a source familiar ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Daniel Scheffler is a Madrid-based travel writer who writes about cultural travel, identity and the human stories that shape how we move through the world. Scheffler is also the host of Without Maps, ...

The festive railcars—which will appear on all five Metra lines this year—will be spreading holiday cheer throughout Chicagoland. You can tell it’s the holidays in Chicagoland when even the trains ...

Teacher Harriet suggests that Daniel and Miss Elaina solve their problem on their own. When Daniel and Miss Elaina can't agree on how to play, Teacher Harriet suggests that they solve the problem on ...

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Henry Chandonnet Every time Henry publishes a story, you’ll get an alert straight to your inbox ...

Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.